Compare Amgen, Inc. (AMGN) vs TeraWulf Inc (WULF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs TeraWulf Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while TeraWulf Inc trades at $21.82 (market cap $10.88B). The key difference: Amgen, Inc. is far larger — about 18× TeraWulf Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.
| AMGN | WULF | |
|---|---|---|
Market Cap | $196.12B | $10.88B |
Sector | Health | Technology |
52-Week High | $388.16 | $28.98 |
52-Week Low | $271.18 | $4.76 |
Enterprise Value | $241.41B | $13.57B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
WULF trades at $21.97, down 5.3% today, amid a bearish technical signal. The stock shows extreme valuation ratios with a P/S of 53.26 and P/B of 84.25, while profitability metrics are deeply negative, including a net income margin of -611.46%. Recent news highlights a major $19 billion, 20-year contract with Anthropic for AI data center infrastructure, signaling a strategic pivot but also high capital expenditure requirements.
The outlook is bifurcated: strong analyst buy consensus and the Anthropic deal offer long-term growth potential in AI infrastructure, but near-term risks include persistent losses, high debt, and execution challenges. Investors face volatility from operational cash burn and market sentiment shifts around AI stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
